title: Pharmacological treatment of HIV-associated pulmonary hypertension.
abstract: Pulmonary arterial hypertension (PAH) is a rare but severe disease that results from chronic obstruction of small pulmonary arteries, leading to right ventricular failure and, ultimately, death. One established risk factor for the development of PAH is HIV infection. The presence of PAH is an independent risk factor for mortality in HIV-infected patients. This article will focus on HIV-associated PAH (HIV-PAH) with special considerations to the available treatments. With the approval of the soluble guanylate cyclase stimulator riociguat, a new drug class has become available in addition to the already existing prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Guidelines for the treatment of idiopathic PAH and guidelines for antiretroviral therapy should be followed for the treatment of HIV-PAH.
authors: a 2nd Infectious Diseases Unit , "L. Spallanzani" National Institute for Infectious Diseases , Rome , Italy.
authors: Pierangelo
authors: P
authors: Chinello
authors: a 2nd Infectious Diseases Unit , "L. Spallanzani" National Institute for Infectious Diseases , Rome , Italy.
authors: Nicola
authors: N
authors: Petrosillo
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000473:pathology
chemical_list: D044966:Anti-Retroviral Agents; D000959:Antihypertensive Agents
keywords: HIV; Pulmonary arterial hypertension; antiretroviral therapy; endothelin receptor antagonists; phosphodiesterase type 5 inhibitors; prostanoids; riociguat; therapy